Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzylpenicillin, also known as penicillin G, is a natural beta-lactam antibiotic used primarily to treat infections caused by gram-positive cocci, especially streptococcal infections. It is administered intravenously or intramuscularly due to poor oral absorption. Benzylpenicillin acts by binding to specific penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting the final stage of cell wall synthesis and leading to bacterial lysis through autolytic enzymes. It is indicated for a wide range of serious infections including pneumonia, strep throat, syphilis, necrotizing enterocolitis, diphtheria, gas gangrene, leptospirosis, cellulitis, tetanus and more. Benzylpenicillin is on the World Health Organization's List of Essential Medicines[2][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzylpenicillin.